The following questions will help us to understand how well our information worked for you, what difference it’s made and what kind of information you’d like to see in the future.

It is normal to have questions about dementia and the diseases that cause it. Here we aim to address some of those questions and hope to challenge some common myths and misconceptions. Many people are ...

Too many people think dementia is just a part of ageing, but the truth is it’s caused by physical diseases. The damage caused by Alzheimer’s can lead to a brain weighing around 140g less than a ...

Our brains control everything we think, feel, remember and do. There are diseases that stop a person’s brain from working properly. When a person has one of these diseases, they may have problems with ...

The information on these pages is for anyone who is concerned about symptoms of dementia, and for those who would like more information about how dementia is diagnosed. Anyone concerned about their ...

Alzheimer’s Research UK supporter and Oldham Athletic owner, Frank Rothwell, has been awarded an OBE for his charitable ...

Find out the 10 most important facts and statistics about dementia and dementia research. Click on each fact for more information. 1. Dementia is not a disease itself. Expand The word ‘dementia’ is a ...

Our brains control everything we think, feel, remember and do. There are diseases that stop a person’s brain from working properly. When a person has one of these diseases, they may have problems with ...

Although often thought of as a condition that only affects older people, it is estimated that around 70,800 people with dementia in the UK are under 65. This is called young onset dementia, and you ...

We have a number of resources and guidelines that can help with experimental design. Delivered by NIHR and supported by Alzheimer's Research UK and Alzheimer's Society, Dementia Researcher is a ...

This week the Government revealed its Spending Review - we dive into what the settlement means for progress on dementia.

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...